Myocor Inc.
about myocortehcnologyclinical cornernews and informationcontact us
Welcome to Myocor®!

The final common pathway for heart disease is the geometric remodeling of the heart. The result of this remodeling is an enlarged, poorly functioning heart with incompetent valves.

Myocor's mission is to develop innovative therapeutic devices to optimize treatment options for patients suffering from diseases associated with geometrically remodeled hearts. The companies proprietary Shape Change Therapy is the focal point for developing products to help restore cardiac function by affecting the geometry of the heart.

The Coapsys&trade System* is Myocor's primary technology. The Coapsys device is intended to provide a complete therapy for the treatment of mitral insufficiency.
LATEST NEWS
ARTICLES





Myocor(R), Inc. Announces Completion of $24 Million Series D Financing

Financing to fund completion of clinical trials for Coapsys&trade device with the potential to benefit patients suffering from a leaking heart valve

Myocor Recognized As One Of The Top 100 Private Companies By The Red Herring Business Journal

Red Herring has a long tradition of discovering new and innovative technology and entrepreneurs. Since 1996, Red Herring editors have selected a group of private companies that are emerging as the brightest stars in the business universe. The Red Herring 100 is not merely a list of companies with attractive financials, but a thorough sifting of ones with the potential to disrupt current markets, or to create entirely new ones.



Myocor® Inc.
*Caution - Investigational device; limited by United States law to investigational use.